Browse

The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.

A dementia prevention trial praised as a "landmark" effort further demonstrated the promise of structured programs tailored to local cultures.

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.